Edition:
United States

Agios Pharmaceuticals Inc (AGIO.O)

AGIO.O on Nasdaq

42.28USD
20 Jan 2017
Change (% chg)

$0.25 (+0.59%)
Prev Close
$42.03
Open
$42.10
Day's High
$42.45
Day's Low
$40.90
Volume
656,849
Avg. Vol
814,697
52-wk High
$67.74
52-wk Low
$33.50

AGIO.O

Chart for AGIO.O

About

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. Its cancer product candidates are AG-221 and... (more)

Overall

Beta: 1.99
Market Cap(Mil.): $1,776.39
Shares Outstanding(Mil.): 42.01
Dividend: --
Yield (%): --

Financials

  AGIO.O Industry Sector
P/E (TTM): -- 44.85 30.38
EPS (TTM): -4.80 -- --
ROI: -36.77 -1.38 14.86
ROE: -47.00 -1.07 16.28

BRIEF-Agios pharmaceuticals AG-120 NDA submission for IDH1M R/R AML planned by year end 2017

* AG-120 NDA submission for IDH1M R/R AML planned by year end 2017

Jan 09 2017

BRIEF-Agios provides early-stage data on AG-120 in glioma, chondrosarcoma patients

* Agios announces phase 1 data from dose expansion cohorts of AG-120 in patients with IDH1 mutant positive glioma and chondrosarcoma Source text for Eikon: Further company coverage:

Nov 18 2016

BRIEF-Agios posts Q3 shr loss $1.63

* Agios Pharmaceuticals inc - now expects to end 2016 with more than $550 million of cash, cash equivalents and marketable securities

Nov 03 2016

BRIEF-Agios Pharma says Celgene expects to submit NDA to U.S. FDA for enasidenib

* Celgene corporation expects to submit a new drug application to U.S. FDA for Enasidenib (ag-221)

Sep 07 2016

BRIEF-Agios Pharmaceuticals appoints Andrew Hirsch as chief financial officer

* Glenn Goddard, senior vice president of finance, will be leaving company at end of September to pursue other opportunities

Aug 16 2016

BRIEF-Agios Pharmaceuticals reports qtrly loss per share $1.47

* Collaboration revenue was $7.0 million for quarter ended June 30, 2016, compared to $13.2 million for comparable period in 2015

Aug 04 2016

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $31.77 +0.07
Novartis AG (NOVN.S) CHF70.90 -0.20
Roche Holding Ltd. (ROG.S) CHF233.50 +0.50
Roche Holding Ltd. (RO.S) CHF236.10 +0.10
Sanofi SA (SASY.PA) €75.62 --
AstraZeneca plc (AZN.L) 4,318.50 -150.00
GlaxoSmithKline plc (GSK.L) 1,546.50 -6.50
Eli Lilly and Co (LLY.N) $76.81 -0.03
Shire PLC (SHP.L) 4,393.00 -90.50
Shire PLC (3159084.L) -- --

Earnings vs. Estimates